Wednesday, May 04, 2022
10:00AM – 11:00AM ET
Please note this TeleECHO program is 10:00AM Eastern, 9:00AM Central, 8:00AM Mountain and 7:00AM Pacific.
PROGRAM OVERVIEW
This live virtual TeleECHO educational series targets healthcare gaps related to the familiarity and understanding of CDK4/6 inhibitor clinical trial designs and results on efficacy, safety, and real-world studies, impacting outcomes through current practice patterns and treatment strategies in the management of HR+/HER2- metastatic breast cancer (mBC).
- By addressing these gaps, you can assess whether your approach to HR+/HER2- mBC management through utilization of current clinical trial and real-word study data to individualize care–could be modified to help close these gaps.
- Expert discussion will guide you in analyzing and identifying challenges to HR+/HER2-mBC management, impact of ESR1 mutation, and how to navigate treatment available options evaluating efficacy and safety.
- You will also be immersed in interactive, animated simulation case studies to memorably highlight key points related to the mechanism of action of CDK4/6 inhibitors and their related safety profiles.
Presenting Faculty:
Sramila Aithal, MD
Medical Oncologist/Hematologist
Alliance Cancer Specialists
US Oncology
Philadelphia, PA
Learning Objectives
After completing the CME activity, learners should be better able to:
- Evaluate the designs of- and results from clinical trials assessing the safety and efficacy of CDK4/6 inhibitors for the management of patients with HR+/HER2- mBC
- Assess the designs of- and results from real-world studies on CDK4/6 inhibitors for the management of patients with HR+/HER2- mBC, as well as current practice patterns regarding their use
- Develop individualized management plans for patients with HR+/HER2- mBC
Target Audience
This initiative is designed to meet the educational needs of community based oncologists and the related cancer care team in community settings including rural and underserved areas responsible for the care of patients with HR+/HER2- mBC.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with HR+/HER2- mBC.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
